

Meeting of ICB Board

Date: Thursday 16 January 2025

Time: 09.30 – 12.00

Location: Virtual, via Microsoft Teams

Agenda Number:	6.5
Title:	Review of updates to ICB Corporate Risk Register
Purpose: Approval	
Key Points for Discussion:	
The ICB Corporate Risk Register (CRR) has been updated to reflect updates to our various Directorate Risk Registers. Risks scoring 15 or above are escalated to the CRR for approval by the ICB Board. The Audit and Risk Committee (ARC) reviewed the CRR at the meeting of 6 December 2024 and recommends to the ICB Board that they approve the content, accepting risks which have been escalated to the CRR and approving the closure or de-escalation of risks which have been resolved or have reduced. De-escalated risks will continue to be managed by Executives as part of the directorate risk register management arrangements.	
Recommendations:	It is recommended that the ICB Board: • Receive the attached CRR • Note the details • Accept the risks escalated to the CRR and approve the closure/de-escalation of risks from the CRR where indicated.
Previously Considered By and feedback :	The CRR has been reviewed by the ICB SLT on 14/8/24 and again on 11/9/24, before being reviewed by the ARC on 6 December 2024. The contributing Directorate Risk Registers have been reviewed by ICB Directors and the CRR risk register has been reviewed by the ARC on 6 December 2024 as part of routine reporting..
Management of Declared Interest:	Not applicable

Risk and Assurance:	The management of our CRR is described in our Risk Management Framework.
Financial / Resource Implications:	The CRR will be subject to ongoing review by ICB Executive Leadership Team in advance of future Committee meetings
Legal, Policy and Regulatory Requirements:	Advice on good practice in Risk Management is included in the HFMA Audit Committee Handbook
How does this reduce Health Inequalities:	No health inequalities issues arising as a result of this report, and there is no impact upon people with protected characteristics. Our Internal Auditors assist in advising on best practice in Population Health Management and Health Inequalities.
How does this impact on Equality & diversity	Our Risk Register can assist in identifying risks to Equality and Diversity, and in managing mitigating actions.
Patient and Public Involvement:	Not applicable to this report.
Communications and Engagement:	This report has not involved any external communications or engagement.
Author(s):	Rob Hayday, Chief of Staff
Sponsoring Director / Clinical Lead / Lay Member:	Shane Devlin, Chief Executive Officer

Appendix 1: ICB Corporate Risk Register, reviewed by ARC meeting on 6 December 2024

[illegible]

[illegible]